Phase 3 Stomach Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given written consent to participate in the study before it begins
• People who have been newly and definitively diagnosed with a type of stomach cancer (gastric adenocarcinoma) or cancer at the junction of the stomach and oesophagus (gastroesophageal junction adenocarcinoma), confirmed by tissue testing
• People who have undergone surgery to remove the cancer, including a wide removal of nearby lymph nodes
• People whose cancer, based on post-surgery staging, is classified as stage IIIB or IV (a specific measure of how far the cancer has spread to nearby lymph nodes)
• People who are able to be enrolled into the trial within 6 weeks after their surgery

Who may not be able to join:

• People who are under 20 years old or 76 years old and above
• People whose general physical functioning is significantly limited (rated at level 2 or higher on a standard medical scale used to measure how much a person's illness affects daily activity — confirm with trial site)
• People who have previously had surgery on their stomach for a tumour
• People with a history of another cancer, with some exceptions: treated skin cancers (basal cell or squamous cell) or early-stage cervical cancer may still be eligible, as may people who completed treatment for another cancer more than 5 years ago and have remained cancer-free since
• People whose stomach or gastroesophageal junction cancer has spread to distant parts of the body (known as M1 metastasis), including certain distant lymph nodes
• People whose surgery left behind detectable cancer (known as R1 or R2 resection)
• People who have previously received chemotherapy, radiotherapy, or immunotherapy for stomach cancer
• People who have taken part in another clinical trial or received an experimental treatment within the 30 days before consenting to this study
• People who, in the 6 months before joining, have had a heart attack, severe or unstable chest pain, heart bypass surgery, serious heart failure, stroke, or a significant heart rhythm problem requiring treatment
• People with uncontrolled seizures, or a nervous system or psychological condition that makes it impossible to give informed consent or to take oral medication reliably
• People with an active, uncontrolled infection or blood poisoning (sepsis)
• People who have had a blood clot in a deep vein within 4 weeks before consenting to join
• People with a serious ongoing illness that could affect their ability to participate or make study results difficult to interpret
• People who have not fully recovered from their surgery
• People who may have difficulty absorbing the study medication taken by mouth, including those with bowel conditions, intestinal blockage, chronic inflammatory bowel disease, a large portion of the small intestine removed, or other conditions affecting absorption (such as gastric dumping syndrome)
• People of childbearing potential who do not agree to use an effective method of contraception during treatment and for at least 6 months after treatment ends
• People who are pregnant, breastfeeding, or who have a positive pregnancy test at the time of joining
• People whose blood and organ test results fall outside the levels required for safe participation — this includes blood cell counts, liver function, kidney function, and related measures (confirm specific values with trial site)
• People with nerve damage in their hands or feet causing symptoms at a moderate or severe level (Grade 2 or higher on a standard medical scale)
• People with a known allergic reaction to any of the study drugs (Docetaxel, Capecitabine, or Oxaliplatin)
• People currently taking medicines that suppress the immune system, or other medications that are not permitted in this trial
• People currently taking blood-thinning medication such as warfarin or similar drugs

Important: Always verify eligibility with the trial site directly before applying.